MRA Advisory Group’s GSK GSK Stock Holding History

MRA Advisory Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,042	Closed	-$287K	–	135
2023 Q2	$287K	Buy	8,042 +915	+13%	+$32.8K	0.2%	88
2023 Q1	$254K	Buy	+7,127	New	+$249K	0.18%	98

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MRA Advisory Group's GSK Position: Q3 2023 in Review

MRA Advisory Group sold out of GSK (GSK) in Q3 2023, closing a stake of 8,042 shares — an estimated $287K sold.

MRA Advisory Group first reported a position in GSK in Q1 2023 and held it in 2 quarters. The position peaked at $287K in Q2 2023. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

MRA Advisory Group reported no remaining GSK position as of Q3 2023 after selling out during the quarter.
MRA Advisory Group sold 8,042 GSK shares in Q3 2023, an estimated $287K.
MRA Advisory Group first reported a position in GSK in Q1 2023 and held it in 2 quarters.
MRA Advisory Group's GSK position peaked at $287K in Q2 2023.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on MRA Advisory Group's 13F filing for Q3 2023, filed 8 Nov 2023.